Ultra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.

Journal: Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Published Date: Dec 4, 2024

Abstract

BACKGROUND: Treatment with sole ultra-low dose rate brachytherapy (uLDR-BT) for unfavorable intermediate risk factor (IUR) group prostate cancer patients is not recommended by guidelines due to the lack of strong evidence of its effectiveness. However, there were numerous patients treated with good results with this method in older trials. Purpose of this work was to retrospectively asses effectiveness of uLDR-BT in IUR group treated in our department.

Authors

  • Adam Kluska
    Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
  • Artur Chyrek
    Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
  • Wojciech Maria Burchardt
    Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
  • Marcin Włodarczyk
    Radiotherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
  • Grzegorz Bielęda
    Electroradiology Department, Poznan University of Medical Sciences, Poznan, Poland.
  • Adam Chicheł
    Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals